Cobitolimod

可比托莫德

Report date: 2025/01/14 16:41:52
NME

Base Information

Drug NameCobitolimod
Drug Alias Namecobitolimodum考托莫德KappaproctCobitolimod sodiumDIMS-0150 +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[32] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIndex
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIndex PharmaceuticalsViatris Pharmaceuticals Japan Inc
Active IndicationsN/A
Inactive IndicationsColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A